Department of Cardiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
NHC Key Laboratory of Assisted Circulation, Sun Yat-Sen University, Guangzhou, China.
Diabetes Metab J. 2021 Sep;45(5):753-764. doi: 10.4093/dmj.2020.0134. Epub 2021 Apr 23.
Currently available guidelines contain conflicting recommendations on the management of blood pressure (BP) in patients with diabetes mellitus (DM). Therefore, it is necessary to appraise the guidelines and summarize the agreements and differences among recommendations.
Four databases and the websites of guideline organizations were searched for guidelines regarding BP targets and thresholds for pharmacologic therapy in DM patients, and the included guidelines were appraised with the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument.
In 6,498 records identified, 20 guidelines met our inclusion criteria with 64.0% AGREE II scores (interquartile range, 48.5% to 72.0%). The scores of the European and American guidelines were superior to those of the Asian guidelines (both adjusted P<0.001). Most of the guidelines advocated systolic BP targets <130 mm Hg (12 guidelines, 60%) and diastolic BP targets <80 mm Hg (14 guidelines, 70%) in DM patients. Approximately half of the guidelines supported systolic BP thresholds >140 mm Hg (10 guidelines, 50%) and diastolic BP thresholds >90 mm Hg (nine guidelines, 45%). The tiny minority of the guidelines provided the relevant recommendations regarding the lower limit of official BP targets and the ambulatory BP monitoring (ABPM)/home BP monitoring (HBPM) targets and thresholds in DM patients.
The lower official BP targets (<130/80 mm Hg) in patients with DM are advocated by most of the guidelines, but they contain conflicting recommendations on the official BP thresholds. Moreover, the gaps regarding the lower limit of official BP targets and the ABPM/HBPM targets and thresholds need to be considered by future study.
目前可用的指南中包含了关于糖尿病患者血压(BP)管理的相互矛盾的建议。因此,有必要对这些指南进行评估,并总结建议之间的一致性和差异。
搜索了四个数据库和指南组织的网站,以获取有关糖尿病患者血压目标和药物治疗阈值的指南,并使用评估指南研究与评价(AGREE)II 工具对纳入的指南进行评估。
在确定的 6498 条记录中,有 20 条指南符合纳入标准,AGREE II 评分(四分位间距为 48.5%至 72.0%)为 64.0%。欧洲和美国的指南评分优于亚洲的指南(均为调整后的 P<0.001)。大多数指南主张糖尿病患者的收缩压目标<130mmHg(12 条指南,60%)和舒张压目标<80mmHg(14 条指南,70%)。大约一半的指南支持收缩压阈值>140mmHg(10 条指南,50%)和舒张压阈值>90mmHg(九条指南,45%)。极少数指南提供了关于糖尿病患者的官方血压目标下限以及动态血压监测(ABPM)/家庭血压监测(HBPM)目标和阈值的相关建议。
大多数指南都主张糖尿病患者的官方血压目标较低(<130/80mmHg),但在官方血压阈值方面存在相互矛盾的建议。此外,未来的研究需要考虑官方血压目标下限以及 ABPM/HBPM 目标和阈值的差距。